Consistent with cholinergic dysfunction contributing to behavioral deficits, Wang et al. (2019) reported that choline supplementation blunted the loss of ChAT + BFCNs and subsequent cognitive deficits in the APP/PS1 mouse model of AD. This evidence concerns the gene APP and Alzheimer disease.